The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Chronic Illness Pub Date : 2024-06-01 Epub Date: 2023-06-07 DOI:10.1177/17423953231180453

Shanbao Zhang, Meng Ouyang, Lei Liu

{"title":"The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis.","authors":"Shanbao Zhang, Meng Ouyang, Lei Liu","doi":"10.1177/17423953231180453","DOIUrl":null,"url":null,"abstract":"Background: Hemodialysis patients are common to have renal anemia in the nephrology practice. For the renal anemia, the high-dose iron from the intravenous route is an important treatment option. We can understand the treatment effects and cardiovascular events of high-dose intravenous iron reviewing the randomized clinical trials.Methods: We compared the high-dose and low-dose iron treatments to find if the high-dose intravenous iron can influence the hematological parameters more significantly than the low-dose iron. The cardiovascular events were also analyzed for the high-dose iron treatment. Six studies with a total of 2422 renal anemia patients under hemodialysis were enrolled. We focused the outcomes of hemoglobin, transferrin saturation percentage, ferritin, erythropoietin dose, and cardiovascular events.Results: The high-dose intravenous iron might be associated with a greater number of ferritin, transferrin saturation percentage, and hemoglobin. In addition, the erythropoietin dose was less needed to maintain the ideal hemoglobin range in the high-dose intravenous iron group.Conclusions: In current meta-analysis, the high-dose intravenous iron might show the superior effects on the ferritin, transferrin saturation percentage, and hemoglobin levels and needed dose of erythropoietin when compared to low-dose iron treatment.","PeriodicalId":48530,"journal":{"name":"Chronic Illness","volume":" ","pages":"221-232"},"PeriodicalIF":1.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Illness","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17423953231180453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hemodialysis patients are common to have renal anemia in the nephrology practice. For the renal anemia, the high-dose iron from the intravenous route is an important treatment option. We can understand the treatment effects and cardiovascular events of high-dose intravenous iron reviewing the randomized clinical trials.

Methods: We compared the high-dose and low-dose iron treatments to find if the high-dose intravenous iron can influence the hematological parameters more significantly than the low-dose iron. The cardiovascular events were also analyzed for the high-dose iron treatment. Six studies with a total of 2422 renal anemia patients under hemodialysis were enrolled. We focused the outcomes of hemoglobin, transferrin saturation percentage, ferritin, erythropoietin dose, and cardiovascular events.

Results: The high-dose intravenous iron might be associated with a greater number of ferritin, transferrin saturation percentage, and hemoglobin. In addition, the erythropoietin dose was less needed to maintain the ideal hemoglobin range in the high-dose intravenous iron group.

Conclusions: In current meta-analysis, the high-dose intravenous iron might show the superior effects on the ferritin, transferrin saturation percentage, and hemoglobin levels and needed dose of erythropoietin when compared to low-dose iron treatment.

查看原文本刊更多论文

大剂量静脉注射铁剂对肾性贫血血液透析患者的治疗效果和心血管事件：系统回顾和荟萃分析。

背景：在肾内科临床中，血液透析患者常见肾性贫血。对于肾性贫血，静脉注射大剂量铁剂是一种重要的治疗方法。通过回顾随机临床试验，我们可以了解大剂量静脉注射铁剂的治疗效果和心血管事件：方法：我们比较了大剂量和小剂量铁剂的治疗效果，以了解大剂量静脉注射铁剂是否比小剂量铁剂对血液学指标的影响更明显。我们还分析了大剂量铁剂治疗的心血管事件。六项研究共纳入了 2422 名接受血液透析的肾性贫血患者。我们重点研究了血红蛋白、转铁蛋白饱和度百分比、铁蛋白、促红细胞生成素剂量和心血管事件的结果：结果：大剂量静脉注射铁剂可能会增加铁蛋白、转铁蛋白饱和度和血红蛋白的数量。此外，大剂量静脉注射铁剂组维持理想血红蛋白范围所需的促红细胞生成素剂量较少：在当前的荟萃分析中，与小剂量铁剂治疗相比，大剂量静脉注射铁剂可能对铁蛋白、转铁蛋白饱和度百分比和血红蛋白水平以及所需的促红细胞生成素剂量有更好的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chronic Illness Multiple-

CiteScore

3.80

自引率

0.00%

发文量

期刊介绍： Chronic illnesses are prolonged, do not resolve spontaneously, and are rarely completely cured. The most common are cardiovascular diseases (hypertension, coronary artery disease, stroke and heart failure), the arthritides, asthma and chronic obstructive pulmonary disease, diabetes and epilepsy. There is increasing evidence that mental illnesses such as depression are best understood as chronic health problems. HIV/AIDS has become a chronic condition in those countries where effective medication is available.